AddLife AB Class B (SE:ALIF.B)
:ALIF.B
Top Page
AddLife AB
(ALIF.B)
Select Model
Select Model
Rating:61Neutral
Price Target:
kr143.00
▼(-7.80% Downside)
Action:ReiteratedDate:02/07/26
The score is driven primarily by improving financial quality—especially strong and improving cash generation and a strengthening leverage profile—supported by a generally positive earnings-call outlook emphasizing further margin improvement and balance-sheet capacity. Offsetting this are inconsistent top-line performance and a mixed technical setup with negative momentum, alongside a relatively expensive valuation (high P/E and low dividend yield).
Positive Factors
Strong free cash flow generation
Consistently high free-cash-flow conversion and strong operating cash flow create durable internal funding for capex, working capital and returns. This strengthens resilience versus revenue swings, supports disciplined M&A and debt paydown, and preserves strategic optionality over the next 2–6 months.
Negative Factors
Inconsistent revenue growth and volatile profitability
Sharp top-line swings and uneven profit recovery reduce earnings visibility and make margin targets harder to sustain. With revenue drivers mixed, shortfalls in instrument or geographic demand can quickly erode operating leverage, complicating planning for investments and M&A over the next few quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong free cash flow generation
Consistently high free-cash-flow conversion and strong operating cash flow create durable internal funding for capex, working capital and returns. This strengthens resilience versus revenue swings, supports disciplined M&A and debt paydown, and preserves strategic optionality over the next 2–6 months.
Read all positive factors
AddLife AB (ALIF.B) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr17.54B
Dividend Yield0.46%
Average Volume (3M)97.37K
Price to Earnings (P/E)34.6
Beta (1Y)0.63
Revenue Growth5.14%
EPS Growth236.75%
CountrySE
Employees2,251
SectorHealthcare
Sector Strength45
IndustryMedical - Instruments & Supplies
Share Statistics
EPS (TTM)2.12
Shares Outstanding117,877,460
10 Day Avg. Volume108,367
30 Day Avg. Volume97,373
Financial Highlights & Ratios
PEG Ratio0.28
Price to Book (P/B)3.56
Price to Sales (P/S)1.86
P/FCF Ratio17.04
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)7.27
Revenue Forecast (FY)kr10.77B
AddLife AB Business Overview & Revenue Model
Company Description
AddLife AB (publ), together with its subsidiaries, provides equipment, medical devices, and reagents primarily to healthcare system, research, colleges, and universities, as well as the food and pharmaceutical industries. The company operates in t...
How the Company Makes Money
AddLife makes money mainly by distributing and selling life science and healthcare products sourced from third-party manufacturers, complemented by recurring sales of consumables and service-related income. A substantial share of revenue comes fro...
AddLife AB Earnings Call Summary
Earnings Call Date:Feb 04, 2026
(Q4-2025)
| % Change Since: |
Next Earnings Date:Apr 28, 2026
Earnings Call Sentiment Positive
The call conveyed a generally positive tone: clear and continuous margin improvement, strong operating cash flow, meaningful net-debt reduction (net debt-to-EBITDA 2.2), and an active, disciplined M&A pipeline. These positives offset material near-term headwinds from currency effects, some weaker instrument and geographic pockets, and one-off impacts from strikes and a divestment/hand-over of a UK endoscopy business. Management emphasized ongoing margin initiatives, portfolio upgrades and confidence in picking up acquisition activity in 2026.Positive Updates
Improved Profitability and Margins
Adjusted EBITA margin improved to 12.4% in the quarter (vs 12.3% a year ago) and the full-year EBITA margin rose to ~12.1% (up from 11.3% the prior year and 10.5% in 2023). Labtech Q4 margin remained strong at 14.1% and Medtech Q4 margin improved to 12.0% (from 11.6%). Full-year margins: Labtech ~12.5% and Medtech ~12.4%.
Negative Updates
Significant Currency Headwinds
Reported revenue in the quarter was down ~5% (currency headwind) and EBITA was negatively impacted (cited ~7% impact). Including currencies, some reported sales growth was negative (management noted sales growth including currencies was down ~3% in the quarter).
Read all updates
Q4-2025 Updates
Positive
Negative
Improved Profitability and Margins
Adjusted EBITA margin improved to 12.4% in the quarter (vs 12.3% a year ago) and the full-year EBITA margin rose to ~12.1% (up from 11.3% the prior year and 10.5% in 2023). Labtech Q4 margin remained strong at 14.1% and Medtech Q4 margin improved to 12.0% (from 11.6%). Full-year margins: Labtech ~12.5% and Medtech ~12.4%.
Read all positive updates
Company Guidance
Management reiterated guidance to continue the profit-improvement agenda into 2026, aiming to drive further EBITA margin expansion (group FY EBITA 12.1%; Q4 adjusted EBITA 12.4%; Labtech Q4 14.1%/FY 12.5%; Medtech Q4 12.0%/FY 12.4%) while pursuing both organic and M&A-led growth (2025: organic +10%, acquisitions +2%; total EBITA growth 8%). They signalled continued deal activity—having closed Pharmacold and Opitek in December—with a return to a roughly 50/50 organic/acquisition contribution over time and a preferred deal size in the EUR 10–30m turnover range, enabled by a strengthened balance sheet (net debt down ~SEK 900m in 2025 and ~SEK 800m in Q4; net debt/EBITDA 2.2, net debt/adj. EBITA 2.5, target ≤3). Cash generation and working-capital efficiency remain priorities (operating cash flow ~SEK 900m in Q4 and SEK 1.4bn FY; cash conversion 111% FY, 98% excluding disposals, a more realistic ~95% going forward; working-capital release SEK 426m in Q4; inventory/sales 16% vs 17% in 2024), and management reiterated long‑term targets of 15% year‑over‑year profit improvement and profit/working capital above 45% (2025: 62%).AddLife AB Financial Statement Overview
Summary
Income Statement
58
Neutral
Balance Sheet
62
Positive
Cash Flow
71
Positive
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 10.44B | 10.29B | 9.69B | 9.08B | 7.99B |
| Gross Profit | 3.98B | 3.86B | 3.60B | 3.43B | 2.86B |
| EBITDA | 1.80B | 1.52B | 1.53B | 1.45B | 1.46B |
| Net Income | 560.00M | 252.00M | 190.00M | 480.00M | 719.00M |
Balance Sheet | |||||
| Total Assets | 12.71B | 13.05B | 12.74B | 13.06B | 10.60B |
| Cash, Cash Equivalents and Short-Term Investments | 813.00M | 331.00M | 272.00M | 376.00M | 345.30M |
| Total Debt | 4.77B | 5.07B | 5.29B | 5.59B | 4.10B |
| Total Liabilities | 7.26B | 7.75B | 7.79B | 8.09B | 6.30B |
| Stockholders Equity | 5.44B | 5.31B | 4.96B | 4.97B | 4.29B |
Cash Flow | |||||
| Free Cash Flow | 1.14B | 798.00M | 465.00M | 627.00M | 866.30M |
| Operating Cash Flow | 1.39B | 1.09B | 773.00M | 909.00M | 1.01B |
| Investing Cash Flow | -497.00M | -386.00M | -317.00M | -1.09B | -2.98B |
| Financing Cash Flow | -305.00M | -682.00M | -554.00M | 134.00M | 2.07B |
AddLife AB Technical Analysis
Neutral
155.10
Price Trends
142.07
Positive
156.00
Negative
168.64
Negative
Market Momentum
-0.70
Negative
54.58
Neutral
83.01
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:ALIF.B, the sentiment is Neutral. The current price of 155.1 is above the 20-day moving average (MA) of 139.27, above the 50-day MA of 142.07, and below the 200-day MA of 168.64, indicating a neutral trend. The MACD of -0.70 indicates Negative momentum. The RSI at 54.58 is Neutral, neither overbought nor oversold. The STOCH value of 83.01 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for SE:ALIF.B.
AddLife AB Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | kr14.16B | 87.10 | 19.59% | ― | 37.41% | 67.03% | |
63 Neutral | kr15.31B | 46.90 | 4.54% | ― | 17.13% | ― | |
61 Neutral | kr17.54B | 34.62 | 7.24% | 0.46% | 5.14% | 236.75% | |
56 Neutral | kr1.07B | -74.03 | -4.20% | ― | 21.71% | -80.37% | |
54 Neutral | kr20.63B | 546.38 | 3.08% | 4.25% | -0.90% | -70.95% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | kr12.79B | -3.70 | 3.34% | 0.80% | -1.29% | ― |
* Healthcare Sector Average
SE:ALIF.B
AddLife AB
143.80
6.15
4.47%
SE:EKTA.B
Elekta AB
54.00
11.59
27.33%
SE:VITR
Vitrolife AB
94.40
-51.03
-35.09%
SE:BONEX
BONESUPPORT HOLDING AB
215.00
-73.60
-25.50%
SE:PAX
Paxman AB
46.00
-16.60
-26.52%
SE:VIMIAN
Vimian Group AB
29.10
-8.50
-22.61%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.